ATAI241220C500
- 1.30
- 0.000.00%
ATAI Life Sciences Newsroom
ATAI Life Sciences Price Target Maintained With a $11.00/Share by Canaccord Genuity
ATAI Life Sciences Is Maintained at Buy by Canaccord Genuity
ATAI Life Sciences Analyst Ratings
Maxim Group Maintains ATAI Life Sciences(ATAI.US) With Buy Rating, Maintains Target Price $6
Express News | U.S.-Listed Shares of ATAI Life Sciences up 9.1%
RFK and the 'MAHA Trade': Vaccine Makers Down, Psychedelic Shares up
ATAI Life Sciences | 10-Q/A: Quarterly report (Amendment)
TD Cowen Maintains ATAI Life Sciences(ATAI.US) With Buy Rating
ATAI Life Sciences | 10-Q: Q3 2024 Earnings Report
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
Atai Life Sciences Advances Therapeutic Pipeline in Q3 With FDA Approval of VLS-01 | NASDAQ:ATAI, ETR:9VC
ATAI Life Sciences | 8-K: atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
ATAI Life Sciences 3Q Research and Development Expenses $12.4M >ATAI
ATAI Life Sciences 3Q Loss/Shr 16c >ATAI
Press Release: Atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Is Atai Life Sciences (NASDAQ:ATAI) Weighed On By Its Debt Load?
Massachusetts Psychedelics Legalization Initiative Poised to Fail
Massachusetts may become the next stop for legalization, is it a good investment opportunity for psychedelic drug concept stocks?
On Tuesday, Massachusetts voters will decide whether the state will legalize psilocybin, a hallucinogenic compound found in "magic mushrooms," worth noting for related concept stocks.
Legalizing Psychedelics: Is Massachusetts Next?